Insider · CIK 0001202770
James Caruso V
Files at CLRB (Cellectar Biosciences, Inc.). First filing Jul 3, 2025, latest May 11, 2026.
In brief
James Caruso V files SEC Form 4 as CEO, president and director at CLRB (Cellectar Biosciences, Inc.). Since Jul 3, 2025, James Caruso V has reported 2 open-market buys worth $75k and 0 open-market sells worth $0, the latest filed on May 11, 2026.
A track record needs three past buys with six months of prices behind them; James Caruso V has 0, so none is measured yet.
The newest scored trade: bought $25k of CLRB on May 7, 2026, filed May 11, 2026, scored 51 (moderate). In the last 12 months: 1 buy worth $25k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CLRB: Cellectar Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | Cellectar Biosciences, Inc. | $25k 8,680 shares | +75% | +32% from low-76% from high | |
| 75Notable | Cellectar Biosciences, Inc. | $50k 10,000 shares | +611% | 0% from low-93% from high |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | CLRB Cellectar Biosciences, Inc. | AGrant or award Stock option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jul 8, 2026 |
| May 7, 2026 | CLRB Cellectar Biosciences, Inc. | POpen-market purchase Common Stock | +8,680 | $2.88 | $25k | 20,318 | May 11, 2026 |
| May 7, 2026 | CLRB Cellectar Biosciences, Inc. | POpen-market purchase Warrantsderivative | +26,040 | $0.01 | $260 | 36,076 | May 11, 2026 |
| Jul 2, 2025 | CLRB Cellectar Biosciences, Inc. | POpen-market purchase Common Stock | +10,000 | $4.99 | $50k | 11,638 | Jul 3, 2025 |
| Jul 2, 2025 | CLRB Cellectar Biosciences, Inc. | POpen-market purchase Warrantsderivative | +10,000 | $0.01 | $100 | 10,000 | Jul 3, 2025 |
| Feb 14, 2025 | CLRB Cellectar Biosciences, Inc. | AGrant or award Stock option (right to buy)derivative | +900,000 | $0.00 | $0 | 900,000 | Feb 18, 2025 |
| Jun 14, 2024 | CLRB Cellectar Biosciences, Inc. | AGrant or award Stock option (right to buy)derivative | +900,000 | $0.00 | $0 | 900,000 | Jun 18, 2024 |
| Dec 8, 2023 | CLRB Cellectar Biosciences, Inc. | AGrant or award Common Stock | +40,596 | $0.00 | $0 | 49,236 | Dec 12, 2023 |
| Jun 23, 2023 | CLRB Cellectar Biosciences, Inc. | AGrant or award Stock option (right to buy)derivative | +261,000 | $0.00 | $0 | 261,000 | Dec 12, 2023 |
Questions about James Caruso V
Answered from the filings on this page, as of the latest one.
Is James Caruso V buying or selling?
In the last 12 months James Caruso V reported 1 open-market buy worth $25k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $25k of CLRB on May 7, 2026. Grants, option exercises and tax withholding are not counted.
How did James Caruso V's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Caruso V has 0.
Where does James Caruso V file Form 4?
James Caruso V has filed Form 4 at CLRB (Cellectar Biosciences, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.